Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies

Keyphrases

• Hematological Malignancies 100%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 100%
• Cellular Immunotherapy 100%
• Adoptive Immunotherapy 75%
• Lymphocytes 50%
• Transfusion 50%
• Donor-derived Cells 50%
• Family Members 25%
• T Cells 25%
• High Risk 25%
• Malignancy 25%
• Natural Killer Cells 25%
• Lymphoma 25%
• Recurrent Disease 25%
• T Cell Lines 25%
• NKT Cells 25%
• Donor Lymphocytes 25%
• Leukemia 25%
• Effector Cells 25%
• T Cell Clone 25%
• HLA-matched Donor 25%
• Chimera 25%
• Hematopoietic Stem Cells 25%
• HLA-identical Sibling 25%
• Prophylactic Treatment 25%
• Mixed chimerism 25%
• Persistent Disease 25%
• Haploidentical 25%

Medicine and Dentistry

• Hematologic Malignancy 100%
• Allogeneic Stem Cell Transplantation 100%
• Immunotherapy 100%
• T Cell 75%
• Adoptive Immunotherapy 75%
• Lymphocyte 75%
• Diseases 50%
• Recurrent Disease 25%
• Cancer 25%
• Hematopoietic Cell 25%
• Effector Cell 25%
• Leukemia 25%
• Cell Line 25%
• Natural Killer Cell 25%
• Natural Killer T Cell 25%

Immunology and Microbiology

• Adoptive Immunotherapy 100%
• Allogeneic Stem Cell Transplantation 100%
• Immunotherapy 100%
• T Cell 100%
• Lymphocyte 100%
• Natural Killer Cell 33%
• Natural Killer T Cell 33%
• Effector Cell 33%
• Cell Clone 33%
• Cell Line 33%
• Hematopoietic Cell 33%